BBC
Virtus LifeSci Biotech Clinical Trials ETF
Price Chart
Latest Quote
$50.97
+1.06 (+2.12%)
Current Price
| Previous Close | $49.91 |
| Open | $49.10 |
| Day High | $51.41 |
| Day Low | $49.12 |
| Volume | 77,548 |
Fund Information
| Quarterly Dividend / Yield | N/A / 1.24% |
| Net Assets | $52.68M |
| Expense Ratio | 0.65% |
| Category | Health |
| Fund Family | Virtus |
| Net Asset Value | $50.05 |
| Premium/Discount | 1.85% |
| Quarterly Dividend Yield | 1.24% |
| Exchange | PCX |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $51.29 |
| SMA50 | $46.35 |
| SMA200 | $40.30 |
| RSI | 49.67 |
| ATR | 1.7799 |
| Rel Volume | 2.03 |
Performance History
| Week | -4.13% |
| Month | +18.48% |
| Quarter | +9.89% |
| 6 Months | +22.85% |
| YTD | +35.45% |
| Year | +140.01% |
| 3 Years | +114.23% |
| 5 Years | +5.98% |
| 10 Years | +179.38% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $50.97 | 77,548 |
| 2026-07-16 | $49.91 | 41,500 |
| 2026-07-15 | $51.85 | 14,900 |
| 2026-07-14 | $51.57 | 16,000 |
| 2026-07-13 | $51.34 | 68,900 |
| 2026-07-10 | $53.17 | 40,900 |
| 2026-07-09 | $54.87 | 32,600 |
| 2026-07-08 | $53.92 | 64,700 |
| 2026-07-07 | $54.20 | 46,600 |
| 2026-07-06 | $52.80 | 51,100 |
| 2026-07-02 | $52.79 | 13,900 |
| 2026-07-01 | $51.55 | 16,700 |
| 2026-06-30 | $52.69 | 36,100 |
| 2026-06-29 | $52.55 | 25,000 |
| 2026-06-26 | $51.06 | 19,400 |
| 2026-06-25 | $49.64 | 28,000 |
| 2026-06-24 | $49.16 | 46,400 |
| 2026-06-23 | $48.49 | 37,900 |
| 2026-06-22 | $47.73 | 61,400 |
| 2026-06-18 | $45.47 | 22,600 |
About Virtus LifeSci Biotech Clinical Trials ETF
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.
📰 Latest News
Biotech ETF (BBC) Touches a New 52-Week High
Zacks • 2026-06-30T11:00:00Z
Biotech ETFs Put Up Strong Show in 1H 2026: More Gains Ahead?
Zacks • 2026-06-23T16:00:00Z
Biotech ETF (BBC) Touches Fresh 52-Week High
Zacks • 2026-04-10T14:02:00Z
Can ETF Winners of Q4 of 2025 Rally in Q1 of 2026?
Zacks • 2026-01-06T16:00:00ZBiotech ETF (BBC) Hits New 52-Week High
Zacks • 2025-12-01T11:00:00Z
The Zacks Analyst Blog Highlights LLY, EPHE, BBC, HELX, XHS and SURI
Zacks • 2025-11-25T08:44:00Z
Best-Performing ETFs of Last Week: Healthcare Rules
Zacks • 2025-11-24T15:00:00Z
Best-Performing ETFs of Last Week
Zacks • 2025-11-17T12:43:00Z
Biotech ETFs Hovering Around a 52-Week: Here's Why
Zacks • 2025-10-30T13:00:00Z
Trade War or Not, Specific Industry ETFs Are in Sweet Spots
Zacks • 2025-10-16T10:51:00Z
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.